- CERo Therapeutics filed notice it will miss deadline for its fiscal year ended Dec. 31, 2025 annual report on Form 10-K.
- Delay follows engagement of a new independent auditor in February 2026, which needs more time to complete review of 2025 financial statements.
- Company expects to file Form 10-K within 15 calendar days of prescribed due date.
- Preliminary results point to net loss of $19.9 million, versus $8.3 million a year earlier.
- Cash used in operating activities is estimated at $16.2 million, versus $12.9 million in prior year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-038509), on April 01, 2026, and is solely responsible for the information contained therein.
Comments